Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated

Comparative Cost Analysis: Lantheus vs. Corcept (2014-2023)

__timestampCorcept Therapeutics IncorporatedLantheus Holdings, Inc.
Wednesday, January 1, 2014882000176081000
Thursday, January 1, 20151361000157939000
Friday, January 1, 20162058000164073000
Sunday, January 1, 20173554000169243000
Monday, January 1, 20185215000168489000
Tuesday, January 1, 20195504000172526000
Wednesday, January 1, 20205582000200649000
Friday, January 1, 20215281000237513000
Saturday, January 1, 20225385000353358000
Sunday, January 1, 20236481000586886000
Loading chart...

Unleashing the power of data

Cost of Revenue Trends: Lantheus Holdings vs. Corcept Therapeutics

In the evolving landscape of the healthcare sector, understanding cost structures is crucial. Over the past decade, Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated have shown distinct trajectories in their cost of revenue. From 2014 to 2023, Lantheus Holdings experienced a staggering 233% increase in costs, peaking at nearly $587 million in 2023. This reflects their aggressive expansion and scaling efforts. In contrast, Corcept Therapeutics saw a more modest growth of 635% in the same period, reaching approximately $6.5 million in 2023. This indicates a more controlled cost management strategy. The data highlights the contrasting business models and growth strategies of these two companies, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025